EDSA — Edesa Biotech, Inc. - Common Shares
Session close: $2.49. Regular-session share volume: 57,680,713. Change from previous close: +16.36%.
Key developments
Edesa Biotech entered an exclusive licensing agreement with KYORIN Pharmaceutical for paridiprubart in Japan. Edesa receives an upfront payment and is eligible for development, regulatory and sales-based milestones plus tiered double-digit royalties on Japanese net sales. KYORIN will fund development, regulatory and commercialization in Japan for the ARDS indication, while Edesa retains rights outside Japan. The deal was valued at more than one hundred forty million dollars in upfront and potential milestone payments.
Company news Edesa Biotech Enters Exclusive Licensing Agreement with KYORIN Pharmaceutical for Paridiprubart in Japan · Company news Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
News sources
Company news Edesa Biotech Enters Exclusive Licensing Agreement with KYORIN Pharmaceutical for Paridiprubart in Japan · Company news Edesa Biotech Enters Collaboration And License Agreement With Kyorin Pharmaceutical For Paridiprubart In Japan; Deal Valued At $140M+ With Potential Milestone Payments · Company news Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan